Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab + RFA for Advanced Tumors Post-PD-1 Failure
NCT07095803Phase 2Not yet recruiting
- Start
- Aug 2025
- Primary completion
- Feb 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
01
Overview
A Phase 2 trial of ivonescimab in solid tumor (advanced stage). Planned start Aug 2025; status: not yet recruiting.
02
Drugs
ivonescimab
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07095803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07095803.